Abstract: A system and method for identifying abnormal medical images. The system can be configured to receive a medical image, segment an anatomical structure from the medical image to define a segmented dataset, register the segmented dataset to a baseline dataset defining a normal anatomical structure, classify, by an abnormality classifier, whether the anatomical structure within the medical image as either abnormal or normal, wherein the abnormality classifier comprises a machine learning algorithm trained to distinguish between normal and abnormal versions of the anatomical structure in medical images, and based on whether the anatomical structure can be segmented from the medical image, whether the segmented dataset can be registered to the baseline dataset, or a classification associated with the medical image output by the abnormality classifier, flagging the medical image as either normal or abnormal.

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

Abstract: A computer-implemented method is provided for classifying a malignancy risk of a kidney, in particular a human kidney. Imaging data of an anatomy of a subject patient at least partially includes a representation of a kidney of the subject patient. A first neural network segments at least one region of the kidney representation based on the imaging data. A second neural network detects one or more suspected lesions of the segmented kidney representation. A third neural network classifies the detected suspected lesion with a malignancy risk. The third neural network is a deep profiler.

Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

Abstract: Systems and methods for a reduced interaction CT scanning workflow. A sensor is used to capture an image of a patient on the table. Scan parameters are automatically set. A full CT scan is performed without a scout scan. During the full CT scan, the scan parameters are adjusted based on the raw CT measurements from the full CT scan. A radiology report is automatically generated from the results of the full CT scan.

Abstract: Systems and methods are provided for automatic detection and quantification for traumatic bleeding. Image data is acquired using a full body dual energy CT scanner. A machine-learned network detects one or more bleeding areas on a bleeding map from the dual energy CT scan image data. A visualization is generated from the bleeding map. The predicted bleeding areas are quantified, and a risk value is generated. The visualization and risk value are presented to an operator.

Abstract: A framework for sensor-based patient treatment support. In accordance with one aspect, one or more sensors are used to acquire sensor data of one or more objects of interest. The sensor data is then automatically interpreted to generate processing results. One or more actions may be triggered based on the processing results to support treatment of a patient, including supporting medical scanning of the patient.

Abstract: A system and method for identifying abnormal medical images. The system can be configured to receive a medical image, segment an anatomical structure from the medical image to define a segmented dataset, register the segmented dataset to a baseline dataset defining a normal anatomical structure, classify, by an abnormality classifier, whether the anatomical structure within the medical image as either abnormal or normal, wherein the abnormality classifier comprises a machine learning algorithm trained to distinguish between normal and abnormal versions of the anatomical structure in medical images, and based on whether the anatomical structure can be segmented from the medical image, whether the segmented dataset can be registered to the baseline dataset, or a classification associated with the medical image output by the abnormality classifier, flagging the medical image as either normal or abnormal.

Abstract: Systems and methods for a reduced interaction CT scanning workflow. A sensor is used to capture an image of a patient on the table. Scan parameters are automatically set. A full CT scan is performed without a scout scan. During the full CT scan, the scan parameters are adjusted based on the raw CT measurements from the full CT scan. A radiology report is automatically generated from the results of the full CT scan.

Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

Abstract: A framework for sensor-based patient treatment support. In accordance with one aspect, one or more sensors are used to acquire sensor data of one or more objects of interest. The sensor data is then automatically interpreted to generate processing results. One or more actions may be triggered based on the processing results to support treatment of a patient, including supporting medical scanning of the patient.

Abstract: Systems and methods are provided for automatic detection and quantification for traumatic bleeding. Image data is acquired using a full body dual energy CT scanner. A machine-learned network detects one or more bleeding areas on a bleeding map from the dual energy CT scan image data. A visualization is generated from the bleeding map. The predicted bleeding areas are quantified, and a risk value is generated. The visualization and risk value are presented to an operator.

Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Abstract: The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds.

Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.